The STRONG-DM study, sponsored by the University of Texas Southwestern Medical Center, aims to evaluate a pragmatic heart failure screening strategy utilizing NT-proBNP and clinical risk scores among patients with Type 2 Diabetes. This study is particularly relevant given the increasing prevalence of diabetes and associated cardiovascular complications, representing a significant market opportunity for preventive therapies such as SGLT2 inhibitors and GLP-1 agonists. The collaboration with Roche Diagnostics indicates potential for leveraging diagnostic capabilities, which could enhance the commercial viability of the intervention. The outcomes may influence clinical guidelines and reimbursement strategies, impacting market dynamics for heart failure management in diabetic patients.